{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T20:55:04Z","timestamp":1789419304478,"version":"build-2803163510"},"reference-count":66,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,7,24]],"date-time":"2025-07-24T00:00:00Z","timestamp":1753315200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100002426","name":"Telethon Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002426","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["brainanddevelopment.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Brain and Development"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1016\/j.braindev.2025.104384","type":"journal-article","created":{"date-parts":[[2025,6,25]],"date-time":"2025-06-25T12:07:04Z","timestamp":1750853224000},"page":"104384","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Hematopoietic stem cell gene therapy of neurometabolic lysosomal storage diseases"],"prefix":"10.1016","volume":"47","author":[{"given":"Giulia","family":"Consiglieri","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Tucci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Ester","family":"Bernardo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.braindev.2025.104384_bb0005","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1038\/s41576-020-00298-5","article-title":"Gene therapy using haematopoietic stem and progenitor cells","volume":"22","author":"Ferrari","year":"2021","journal-title":"Nat Rev Genet"},{"key":"10.1016\/j.braindev.2025.104384_bb0010","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1056\/NEJMra1706910","article-title":"Gene therapy","volume":"381","author":"High","year":"2019","journal-title":"N Eng J Med"},{"key":"10.1016\/j.braindev.2025.104384_bb0015","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/j.ymthe.2020.12.007","article-title":"Current clinical applications of in vivo gene therapy with AAVs","volume":"29","author":"Mendell","year":"2021","journal-title":"Mol Ther"},{"key":"10.1016\/j.braindev.2025.104384_bb0020","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1016\/j.hoc.2022.03.012","article-title":"Ex vivo and in vivo gene therapy for Mucopolysaccharidoses: state of the art","volume":"36","author":"Consiglieri","year":"2022","journal-title":"Hematol Oncol Clin North Am"},{"key":"10.1016\/j.braindev.2025.104384_bb0025","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1089\/hum.2019.190","article-title":"Gene-based approaches to inherited Neurometabolic diseases","volume":"30","author":"Poletti","year":"2019","journal-title":"Hum Gene Ther"},{"key":"10.1016\/j.braindev.2025.104384_bb0030","doi-asserted-by":"crossref","first-page":"417","DOI":"10.3389\/fnins.2015.00417","article-title":"Neuroinflammatory paradigms in lysosomal storage diseases","volume":"9","author":"Bosch","year":"2015","journal-title":"Front Neurosci"},{"issue":"457","key":"10.1016\/j.braindev.2025.104384_bb0035","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1111\/j.1651-2227.2008.00656.x","article-title":"Substrate reduction therapy","volume":"97","author":"Platt","year":"2008","journal-title":"Acta Paediatr"},{"key":"10.1016\/j.braindev.2025.104384_bb0040","doi-asserted-by":"crossref","first-page":"1775","DOI":"10.3390\/biom11121775","article-title":"Therapeutic approaches in lysosomal storage diseases","volume":"11","author":"Fern\u00e1ndez-Pereira","year":"2021","journal-title":"Biomolecules"},{"key":"10.1016\/j.braindev.2025.104384_bb0045","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1007\/s10545-016-9917-1","article-title":"The impact of the immune system on the safety and efficiency of enzyme replacement therapy in lysosomal storage disorders","volume":"39","author":"Broomfield","year":"2016","journal-title":"J Inherit Metab Dis"},{"key":"10.1016\/j.braindev.2025.104384_bb0050","series-title":"The metabolic and molecular basis of inherited disease","first-page":"3421","author":"Neufeld","year":"2001"},{"key":"10.1016\/j.braindev.2025.104384_bb0055","doi-asserted-by":"crossref","first-page":"433","DOI":"10.3389\/fped.2019.00433","article-title":"Hematopoietic stem cell transplantation in inborn errors of metabolism","volume":"7","author":"Tan","year":"2019","journal-title":"Front Pediatr"},{"key":"10.1016\/j.braindev.2025.104384_bb0060","doi-asserted-by":"crossref","first-page":"v4","DOI":"10.1093\/rheumatology\/ker394","article-title":"Overview of the mucopolysaccharidoses","volume":"50","author":"Muenzer","year":"2011","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.braindev.2025.104384_bb0065","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/j.ymgme.2016.01.011","article-title":"Enzyme replacement therapy prior to haematopoietic stem cell transplantation in Mucopolysaccharidosis type I: 10year combined experience of 2 centres","volume":"117","author":"Ghosh","year":"2016","journal-title":"Mol Genet Metab"},{"key":"10.1016\/j.braindev.2025.104384_bb0070","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1038\/sj.bmt.1705934","article-title":"Combination of enzyme replacement and hematopoietic stem cell transplantation as therapy for hurler syndrome","volume":"41","author":"Tolar","year":"2008","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.braindev.2025.104384_bb0075","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/j.jpeds.2012.07.052","article-title":"Enzyme replacement is associated with better cognitive outcomes after transplant in hurler syndrome","volume":"162","author":"Eisengart","year":"2013","journal-title":"J Pediatr"},{"key":"10.1016\/j.braindev.2025.104384_bb0080","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1097\/01.GIM.0000154299.22120.6A","article-title":"Safety and efficacy of enzyme replacement therapy in combination with hematopoietic stem cell transplantation in hurler syndrome","volume":"7","author":"Grewal","year":"2005","journal-title":"Genet Med"},{"key":"10.1016\/j.braindev.2025.104384_bb0085","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1038\/sj.bmt.1705401","article-title":"Haematopoietic cell transplantation (HCT) in combination with enzyme replacement therapy (ERT) in patients with hurler syndrome","volume":"38","author":"Cox-Brinkman","year":"2006","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.braindev.2025.104384_bb0090","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1016\/j.bbmt.2009.01.020","article-title":"Risk factor analysis of outcomes after unrelated cord blood transplantation in patients with hurler syndrome","volume":"15","author":"Boelens","year":"2009","journal-title":"Biol Blood Marrow Transplantat"},{"key":"10.1016\/j.braindev.2025.104384_bb0095","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.jpeds.2008.07.004","article-title":"Use of enzyme replacement therapy (Laronidase) before hematopoietic stem cell transplantation for Mucopolysaccharidosis I: experience in 18 patients","volume":"154","author":"Wynn","year":"2009","journal-title":"J Pediatr"},{"key":"10.1016\/j.braindev.2025.104384_bb0100","doi-asserted-by":"crossref","first-page":"e226","DOI":"10.1016\/j.bbmt.2019.02.012","article-title":"Hematopoietic stem cell transplantation for Mucopolysaccharidoses: past, present, and future","volume":"25","author":"Taylor","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.braindev.2025.104384_bb0105","doi-asserted-by":"crossref","first-page":"5130","DOI":"10.1182\/blood-2010-04-278234","article-title":"Gene therapy augments the efficacy of hematopoietic cell transplantation and fully corrects mucopolysaccharidosis type I phenotype in the mouse model","volume":"116","author":"Visigalli","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.braindev.2025.104384_bb0110","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.1038\/mt.2013.141","article-title":"Myeloid\/microglial driven autologous hematopoietic stem cell gene therapy corrects a neuronopathic lysosomal disease","volume":"21","author":"Sergijenko","year":"2013","journal-title":"Mol Ther"},{"key":"10.1016\/j.braindev.2025.104384_bb0115","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1056\/NEJMoa2106596","article-title":"Hematopoietic stem- and progenitor-cell gene therapy for hurler syndrome","volume":"385","author":"Gentner","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.braindev.2025.104384_bb0120","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.adi8214","article-title":"Early skeletal outcomes after hematopoietic stem and progenitor cell gene therapy for hurler syndrome","volume":"16","author":"Consiglieri","year":"2024","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.braindev.2025.104384_bb0125","doi-asserted-by":"crossref","first-page":"4854","DOI":"10.3390\/ijms23094854","article-title":"Current and future treatment of Mucopolysaccharidosis (MPS) type II: is brain-targeted stem cell gene therapy the solution for this devastating disorder?","volume":"23","author":"Horgan","year":"2022","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.braindev.2025.104384_bb0130","doi-asserted-by":"crossref","DOI":"10.15252\/emmm.201708730","article-title":"Brain-targeted stem cell gene therapy corrects mucopolysaccharidosis type II via multiple mechanisms","volume":"10","author":"Gleitz","year":"2018","journal-title":"EMBO Mol Med"},{"key":"10.1016\/j.braindev.2025.104384_bb0135","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1007\/BF01800232","article-title":"Bone marrow transplantation for Sanfilippo disease type B","volume":"15","author":"Vellodi","year":"1992","journal-title":"J Inherit Metab Dis"},{"key":"10.1016\/j.braindev.2025.104384_bb0140","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1007\/BF00710053","article-title":"Neuropsychological outcomes of several storage diseases with and without bone marrow transplantation","volume":"18","author":"Shapiro","year":"1995","journal-title":"J Inherit Metab Dis"},{"key":"10.1016\/j.braindev.2025.104384_bb0145","doi-asserted-by":"crossref","first-page":"2979","DOI":"10.1182\/blood-2008-03-140830","article-title":"Unrelated donor umbilical cord blood transplantation for inherited metabolic disorders in 159 pediatric patients from a single center: influence of cellular composition of the graft on transplantation outcomes","volume":"112","author":"Prasad","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.braindev.2025.104384_bb0150","first-page":"63","article-title":"Early umbilical cord blood-derived stem cell transplantation does not prevent neurological deterioration in Mucopolysaccharidosis type III","volume":"18","author":"Welling","year":"2015","journal-title":"JIMD Rep"},{"key":"10.1016\/j.braindev.2025.104384_bb0155","article-title":"Hematopoietic stem cell transplantation in mucopolysaccharidosis type IIIA: a case description and comparison with a genotype-matched control group","volume":"23","author":"K\u00f6hn","year":"2020","journal-title":"Mol Genet Metab Rep"},{"issue":"4 Suppl 1","key":"10.1016\/j.braindev.2025.104384_bb0160","first-page":"231","article-title":"Preliminary outcomes of haematopoietic stem cell gene therapy in a patient with mucopolysaccharidosis IIIA","volume":"28","author":"Kinsella","year":"2020","journal-title":"Mol Ther"},{"key":"10.1016\/j.braindev.2025.104384_bb0165","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbagen.2019.129437","article-title":"Progress in the understanding and treatment of Fabry disease","volume":"1864","author":"Miller","year":"2020","journal-title":"Biochim Biophys Acta Gen Subj"},{"key":"10.1016\/j.braindev.2025.104384_bb0170","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1038\/s41467-021-21371-5","article-title":"Lentivirus-mediated gene therapy for Fabry disease","volume":"12","author":"Khan","year":"2021","journal-title":"Nat Commun"},{"key":"10.1016\/j.braindev.2025.104384_bb0175","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.omtm.2022.09.010","article-title":"IGF2-tagging of GAA promotes full correction of murine Pompe disease at a clinically relevant dosage of lentiviral gene therapy","volume":"27","author":"Liang","year":"2022","journal-title":"Mol Ther Methods Clin Dev."},{"key":"10.1016\/j.braindev.2025.104384_bb0180","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/j.omtm.2022.10.017","article-title":"Screening chimeric GAA variants in preclinical study results in hematopoietic stem cell gene therapy candidate vectors for Pompe disease","volume":"27","author":"Dogan","year":"2022","journal-title":"Mol Ther Methods Clin Dev"},{"key":"10.1016\/j.braindev.2025.104384_bb0185","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.beem.2014.10.001","article-title":"Metachromatic leukodystrophy: disease spectrum and approaches for treatment","volume":"29","author":"van Rappard","year":"2015","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"key":"10.1016\/j.braindev.2025.104384_bb0190","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/j.ymgme.2020.07.002","article-title":"Safety of intrathecal delivery of recombinant human arylsulfatase a in children with metachromatic leukodystrophy: results from a phase 1\/2 clinical trial","volume":"131","author":"Dali","year":"2020","journal-title":"Mol Genet Metab"},{"key":"10.1016\/j.braindev.2025.104384_bb0195","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1007\/s00109-008-0309-3","article-title":"Non-inhibitory antibodies impede lysosomal storage reduction during enzyme replacement therapy of a lysosomal storage disease","volume":"86","author":"Matzner","year":"2008","journal-title":"J Mol Med (Berl)"},{"key":"10.1016\/j.braindev.2025.104384_bb0200","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/s40348-020-00103-7","article-title":"Early clinical course after hematopoietic stem cell transplantation in children with juvenile metachromatic leukodystrophy","volume":"7","author":"Beschle","year":"2020","journal-title":"Mol Cell Pediatr"},{"key":"10.1016\/j.braindev.2025.104384_bb0205","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1186\/s13023-015-0313-y","article-title":"Long-term outcomes after allogeneic hematopoietic stem cell transplantation for metachromatic leukodystrophy: the largest single-institution cohort report","volume":"10","author":"Boucher","year":"2015","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.braindev.2025.104384_bb0210","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1001\/jamaneurol.2016.2067","article-title":"Long-term outcome of allogeneic hematopoietic stem cell transplantation in patients with juvenile metachromatic Leukodystrophy compared with nontransplanted control patients","volume":"73","author":"Groeschel","year":"2016","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.braindev.2025.104384_bb0215","doi-asserted-by":"crossref","first-page":"3070","DOI":"10.1172\/JCI28873","article-title":"Gene therapy of metachromatic leukodystrophy reverses neurological damage and deficits in mice","volume":"116","author":"Biffi","year":"2006","journal-title":"J Clin Invest"},{"key":"10.1016\/j.braindev.2025.104384_bb0220","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1172\/JCI200419205","article-title":"Correction of metachromatic leukodystrophy in the mouse model by transplantation of genetically modified hematopoietic stem cells","volume":"113","author":"Biffi","year":"2004","journal-title":"J Clin Invest"},{"key":"10.1016\/j.braindev.2025.104384_bb0225","doi-asserted-by":"crossref","DOI":"10.1126\/science.1233158","article-title":"Lentiviral hematopoietic stem cell gene therapy benefits metachromatic leukodystrophy","volume":"341","author":"Biffi","year":"2013","journal-title":"Science"},{"key":"10.1016\/j.braindev.2025.104384_bb0230","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1016\/S0140-6736(16)30374-9","article-title":"Lentiviral haemopoietic stem-cell gene therapy in early-onset metachromatic leukodystrophy: an ad-hoc analysis of a non-randomised, open-label, phase 1\/2 trial","volume":"388","author":"Sessa","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.braindev.2025.104384_bb0235","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1016\/S0140-6736(21)02017-1","article-title":"Lentiviral haematopoietic stem-cell gene therapy for early-onset metachromatic leukodystrophy: long-term results from a non-randomised, open-label, phase 1\/2 trial and expanded access","volume":"399","author":"Fumagalli","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.braindev.2025.104384_bb0240","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1093\/brain\/120.8.1485","article-title":"Adrenoleukodystrophy: phenotype, genetics, pathogenesis and therapy","volume":"120","author":"Moser","year":"1997","journal-title":"Brain"},{"key":"10.1016\/j.braindev.2025.104384_bb0245","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1080\/14712598.2022.2124857","article-title":"Treatment of cerebral adrenoleukodystrophy: allogeneic transplantation and lentiviral gene therapy","volume":"22","author":"Gupta","year":"2022","journal-title":"Expert Opin Biol Ther"},{"key":"10.1016\/j.braindev.2025.104384_bb0250","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1186\/1750-1172-7-51","article-title":"X-linked adrenoleukodystrophy (X-ALD): clinical presentation and guidelines for diagnosis, follow-up and management","volume":"7","author":"Engelen","year":"2012","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.braindev.2025.104384_bb0255","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1212\/WNL.0000000000201374","article-title":"International recommendations for the diagnosis and Management of Patients with Adrenoleukodystrophy: a consensus-based approach","volume":"99","author":"Engelen","year":"2022","journal-title":"Neurology"},{"key":"10.1016\/j.braindev.2025.104384_bb0260","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1007\/s11940-019-0605-y","article-title":"The landscape of hematopoietic stem cell transplant and gene therapy for X-linked Adrenoleukodystrophy","volume":"21","author":"Mallack","year":"2019","journal-title":"Curr Treat Options Neurol"},{"key":"10.1016\/j.braindev.2025.104384_bb0265","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1182\/blood-2003-10-3402","article-title":"Cerebral X-linked adrenoleukodystrophy: the international hematopoietic cell transplantation experience from 1982 to 1999","volume":"104","author":"Peters","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.braindev.2025.104384_bb0270","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1016\/j.bbmt.2018.09.036","article-title":"Survival and functional outcomes in boys with cerebral Adrenoleukodystrophy with and without hematopoietic stem cell transplantation","volume":"25","author":"Raymond","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.braindev.2025.104384_bb0275","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1111\/bjh.18179","article-title":"Haematopoietic stem cell gene therapy in inborn errors of metabolism","volume":"198","author":"Chiesa","year":"2022","journal-title":"Br J Haematol"},{"key":"10.1016\/j.braindev.2025.104384_bb0280","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1126\/science.1171242","article-title":"Hematopoietic stem cell gene therapy with a lentiviral vector in X-linked adrenoleukodystrophy","volume":"326","author":"Cartier","year":"2009","journal-title":"Science"},{"key":"10.1016\/j.braindev.2025.104384_bb0285","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1056\/NEJMoa2405541","article-title":"Hematologic Cancer after gene therapy for cerebral Adrenoleukodystrophy","volume":"391","author":"Duncan","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.braindev.2025.104384_bb0290","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1056\/NEJMoa2400442","article-title":"Lentiviral gene therapy for cerebral Adrenoleukodystrophy","volume":"391","author":"Eichler","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.braindev.2025.104384_bb0295","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1038\/s41409-020-01125-5","article-title":"Neurocognitive functioning in long-term survivors of pediatric hematopoietic cell transplantation","volume":"56","author":"Parris","year":"2021","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.braindev.2025.104384_bb0300","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1053\/j.semperi.2015.03.005","article-title":"Newborn screening for lysosomal storage disorders","volume":"39","author":"Matern","year":"2015","journal-title":"Semin Perinatol"},{"key":"10.1016\/j.braindev.2025.104384_bb0305","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1038\/s41467-018-08201-x","article-title":"Selective hematopoietic stem cell ablation using CD117-antibody-drug-conjugates enables safe and effective transplantation with immunity preservation","volume":"10","author":"Czechowicz","year":"2019","journal-title":"Nat Commun"},{"key":"10.1016\/j.braindev.2025.104384_bb0310","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1038\/nbt.3584","article-title":"Non-genotoxic conditioning for hematopoietic stem cell transplantation using a hematopoietic-cell-specific internalizing immunotoxin","volume":"34","author":"Palchaudhuri","year":"2016","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.braindev.2025.104384_bb0315","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1016\/j.ymthe.2019.12.009","article-title":"Retroviral insertional mutagenesis in humans: evidence for four genetic mechanisms promoting expansion of cell clones","volume":"28","author":"Bushman","year":"2020","journal-title":"Mol Ther"},{"key":"10.1016\/j.braindev.2025.104384_bb0320","doi-asserted-by":"crossref","first-page":"1985","DOI":"10.1038\/s41591-022-01934-9","article-title":"Ensuring a future for gene therapy for rare diseases","volume":"28","author":"Aiuti","year":"2022","journal-title":"Nat Med"},{"key":"10.1016\/j.braindev.2025.104384_bb0325","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1056\/NEJMoa1700554","article-title":"Hematopoietic stem-cell gene therapy for cerebral Adrenoleukodystrophy","volume":"377","author":"Eichler","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.braindev.2025.104384_bb0330","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1038\/s41591-023-02208-8","article-title":"Access to gene therapy for rare diseases when commercialization is not fit for purpose","volume":"29","author":"Fox","year":"2023","journal-title":"Nat Med"}],"container-title":["Brain and Development"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S038776042500066X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S038776042500066X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,12,11]],"date-time":"2025-12-11T12:32:08Z","timestamp":1765456328000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S038776042500066X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8]]},"references-count":66,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["S038776042500066X"],"URL":"https:\/\/doi.org\/10.1016\/j.braindev.2025.104384","relation":{},"ISSN":["0387-7604"],"issn-type":[{"value":"0387-7604","type":"print"}],"subject":[],"published":{"date-parts":[[2025,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Hematopoietic stem cell gene therapy of neurometabolic lysosomal storage diseases","name":"articletitle","label":"Article Title"},{"value":"Brain and Development","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.braindev.2025.104384","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Japanese Society of Child Neurology. Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"104384"}}